Nanobiotix S.A.
NBTX
$20.44
$0.683.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.02M | -2.81M | -12.58M | 13.07M | 39.20M |
| Total Other Revenue | 3.27M | 3.98M | 4.78M | 5.63M | 6.47M |
| Total Revenue | 11.29M | 1.17M | -7.80M | 18.70M | 45.67M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 11.29M | 1.17M | -7.80M | 18.70M | 45.67M |
| SG&A Expenses | 22.85M | 22.26M | 22.19M | 23.04M | 23.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.82M | 61.83M | 66.05M | 68.09M | 69.86M |
| Operating Income | -47.53M | -60.65M | -73.85M | -49.39M | -24.19M |
| Income Before Tax | -56.01M | -64.65M | -73.62M | -55.12M | -35.92M |
| Income Tax Expenses | -39.90K | 34.20K | 109.20K | 195.10K | 282.40K |
| Earnings from Continuing Operations | -55.97 | -64.69 | -73.73 | -55.32 | -36.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.97M | -64.69M | -73.73M | -55.32M | -36.20M |
| EBIT | -47.53M | -60.65M | -73.85M | -49.39M | -24.19M |
| EBITDA | -46.90M | -59.75M | -72.67M | -48.23M | -23.04M |
| EPS Basic | -1.18 | -1.37 | -1.56 | -1.20 | -0.83 |
| Normalized Basic EPS | -0.79 | -0.92 | -1.05 | -0.74 | -0.42 |
| EPS Diluted | -1.18 | -1.37 | -1.56 | -1.20 | -0.83 |
| Normalized Diluted EPS | -0.79 | -0.92 | -1.05 | -0.74 | -0.42 |
| Average Basic Shares Outstanding | 189.65M | 189.35M | 189.06M | 180.47M | 171.89M |
| Average Diluted Shares Outstanding | 189.65M | 189.35M | 189.06M | 180.47M | 171.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |